| |
Explore dynamic forces reshaping how therapies reach patients and gain actionable insights on market access and patient support from industry experts in this podcast series from Asembia's AXS25 Summit. Listen now. .png)
|
|
Today’s Big NewsMay 6, 2025 |
|
Wednesday, May 14, 2025 | 11am ET / 8am PT Biotech success isn’t just about great science—it’s about building a compelling commercial narrative from day one. Join us to explore how early commercialization planning, powered by real-world insights, can maximize an asset’s potential. Our discussion will uncover strategies to integrate commercial thinking into R&D. Register now. |
|
| By Ben Adams Just four months after Eli Lilly and British biotech Alchemab penned a discovery collaboration, the Big Pharma is licensing its first drug asset from the deal. |
|
|
|
By Nick Paul Taylor Mersana Therapeutics only has eyes for Emi-Le. Seeking to extend its cash runway into mid-2026, the biotech is laying off 55% of its employees and cutting back internal R&D work to focus on lead program emiltatug ledadotin. |
By Gabrielle Masson The National Institutes of Health has laid off 250 more employees, with this round of cuts also hitting 50 workers at the National Cancer Institute. |
Sponsored by 89bio How a commonly “silent disease” is driving urgency and novelty in the liver disease treatment paradigm and what can we hope for. |
|
No matter where you are in your biologics development journey, you need reliable, high-quality analytical data to move forward with confidence. Our full-spectrum analytical testing services are designed to meet your evolving needs, from early to late stage clinical and beyond. 
|
|
By Gabrielle Masson Nineteen states and the District of Columbia have filed a new lawsuit against HHS Secretary Robert F. Kennedy Jr. in hopes of stopping the dismantling of the agency. |
By Darren Incorvaia Anti-aging biotech NewLimit plans to push a liver-rejuvenating mRNA medicine into the clinic with the aid of a $130 million series B fundraising round. |
By Nick Paul Taylor PTC Therapeutics reported a phase 2 win for its Novartis-partnered Huntington's disease candidate. But the readout failed to convince investors, who wiped almost 20% off PTC’s share price amid doubts about the path to accelerated approval of the asset. |
By Nick Paul Taylor A phase 3 trial of Aldeyra Therapeutics’ dry eye disease prospect has hit its primary endpoint, teeing the biotech to seek approval for a candidate that the FDA has rejected twice in recent years. Another phase 3 trial missed its primary endpoint but Aldeyra said the data can still support its latest resubmission. |
By Ben Adams Capricor Therapeutics saw its shares fall 13% by the end of trading Monday as its investigational cell therapy deramiocel for DMD was revealed as the first drug expected to face an FDA advisory committee under the new agency’s commissioner, Marty Makary, M.D. |
By Fraiser Kansteiner BMS is laying off 516 workers who report to the company in Lawrenceville, New Jersey, according to a new Worker Adjustment and Retraining Notification Act notice filed with the state. |
By Darren Incorvaia Biomea Fusion is following through on a New Year’s resolution to become a metabolic-focused company. The Bay Area biotech has dropped a phase 1 leukemia candidate and laid off 35% of staff to focus development on diabetes and obesity assets, the company announced in a May 5 release. |
By Zoey Becker Both companies are working on workforce optimization efforts, prompting a headcount reduction of 24 at Mammoth and sweeping changes across Unity's workforce. |
By Noah Tong Health plans and employers view cell and gene affordability as a significant challenge. Next month, the CMS will announce states participating in a new model to address financial concerns by states and payers. |
By Angus Liu In President Donald Trump’s latest push to bring pharmaceutical manufacturing to the U.S., a new executive order tasks the FDA with reducing regulatory hurdles for domestic producers while making life harder for foreign manufacturers. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," hear how the founders of ElevAAte are turning shared East Asian American experiences into collective power for the next generation of biopharma leaders. |
|
|---|
|
|
|
Thursday, May 15, 2025 | 12pm ET / 9am PT Join this webinar for a deep dive into today’s biotech investment climate and practical strategies to navigate commercialization when pharma partnerships are delayed or uncertain. 
|
|
Whitepaper Don’t delay your gene transfer trial’s start-up timeline by gaining the latest insights from WCG’s case study on the power of a seamless Institutional Review Board (IRB) and Institutional Biosafety Committee (IBC) review process. Sponsored by: WCG |
Whitepaper Learn how the SpyLock service can offer fast bispecific generation, reduce workload, and accelerate candidate selection. - Learn how the SpyTag/SpyCatcher protein ligation system was engineered into SpyLock technology to streamline bispecific antibody generation
- Discover how SpyLock technology reduces workload by enabling rapid bispecific assembly and accelerating candidate selection
- Explore a real-world case study of constructing anti-PD1/PD-L1 bispecific antibodies using SpyLock for functional screening.
Sponsored by: Bio-Rad |
Whitepaper We interviewed 24 Medical Affairs leaders on the critical success factors for building a Best Practice Medical Affairs organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
eBook Typical vaccine development timelines have averaged 10 years, but the time from the SARS-CoV-2 genetic sequence’s release to the submission of the first vaccine clinical trial data for regulatory review was a mere 314 days. In IQVIA Laboratories’ Vaccine eBook we focus on how contract research organizations (CROs) can best leverage strategic partnerships with sponsors to prepare for the next pandemic. Sponsored by: IQVIA |
| |
|
